Response to alectinib after one year of discontinuation of crizotinib in anaplastic lymphoma kinase-positive non-small-cell lung cancer: A case report

Therapy with crizotinib achieves prolonged progression-free and overall survival in non-small-cell lung cancer (NSCLC) patients with echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK). It was demonstrated that ALK-positive NSCLCs exhibit a high response rate to...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Mol Clin Oncol
Autores principales: WATANABE, HIROKO, TAMURA, TOMOHIRO, SHIOZAWA, TOSHIHIRO, OHARA, GEN, KAGOHASHI, KATSUNORI, KAWAGUCHI, MIO, KURISHIMA, KOICHI, SATOH, HIROAKI, HIZAWA, NOBUYUKI
Formato: Artigo
Lenguaje:Inglês
Publicado: D.A. Spandidos 2015
Materias:
Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4487038/
https://ncbi.nlm.nih.gov/pubmed/26171201
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2015.531
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares